The Analysis of Heart Rate Variability With 24hrs Holter ECG and Serum Cardiac Fibrosis Markers in Critical Illness Patients Who Are With Cardiogenic Shock, With ECMO or IABP Support, or With APACH II Score >25)

N/ACompletedNCT01993745

National Taiwan University Hospital106 enrolled

Overview

The study is to show the prognostic factor of HRV parameter and cardiac fibrosis markers in critical illness patients

The analysis of Heart Rate Variability with 24hrs Holter ECG and serum cardiac fibrosis markers in critical illness patients who are with cardiogenic shock, with ECMO or IABP support, or with APACH II score \>25)

Study Type

OBSERVATIONAL

Enrollment

106

Conditions

Cardiogenic Shock,With ECMO or IABP Support,With APACH II Score >25)

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * critical illness patients who are with cardiogenic shock, with ECMO or IABP support, or with APACH II score \>25) Exclusion Criteria: * pacemaker rhythm, not sign the permit

Locations (1)

National Taiwan University Hospital

Taipei, Taipei, Taiwan

Outcomes

Primary Outcomes

Heart Rate Variability and serum cardiac fibrosis markers in critical illness patients

1. Outcome measurement: The measure is a composite outcome measure consisting of multiple measures (results to be reported as a single value for each Arm/Group), no changes are required 2. List the primary condition or disease being studied Shock needing ECMO support

Time frame: 2-4weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.